<PAGE>
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF
THE SECURITIES ACT OF 1934
DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): JULY 8, 1998
NEUROMEDICAL SYSTEMS, INC.
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)
Delaware 0-26984 13-3526980
(State or other (Commission File No.) (I.R.S. Employer
jurisdiction Identification No.)
of incorporation
Two Executive Boulevard, Suite 306
Suffern, New York 10901-4164
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (914) 368-3600
<PAGE>
ITEM 5.
- -------
NEUROMEDICAL SYSTEMS, INC. ANNOUNCES US BUSINESS UNIT RESTRUCTURING
- -------------------------------------------------------------------
On July 8, 1998, Neuromedical Systems, Inc. (the "Company") announced a
restructuring of its US business unit and some related corporate functions.
These changes will allow the Company to more efficiently service its customers
and continue to implement strategies developed to support its laboratory-
oriented business plan.
Through constructive input from the Company's US laboratory customer base,
the Company has developed multiple pricing programs and customer-service
oriented support systems that allow Company customers to most effectively
utilize the PapNet test in their laboratories. As a result, the Company
believes its operations will become more efficient, and anticipates this to be
reflected in a continued reduction in the Company's cash-burn rate.
The US business unit is taking its cues from the Company's European
business unit which has introduced its laboratory focused PAPNET(R)-on-Cyte(TM)
program with much success. The Company has learned from its European customer
base that the early adopters of the PapNet test were also the first to implement
the PapNet technology on site in their laboratories. These innovators were also
the first to integrate the PapNet test used in a primary screening mode into
their Pap smear screening programs.
The Company is on schedule to commence its US primary screening trial this
month. The Company expects that those US customers who have adopted and
presently use the PapNet test in its currently FDA approved rescreening mode are
likely to be the first in the US to adopt PapNet assisted primary screening upon
approval by the FDA. The Company believes that the combination of the robust
nature of its technology and the broad applications of its patents offers an
opportunity to become a leading supplier of anatomic pathology equipment to the
laboratory market.
The restructuring is predicated on the Company's goals of being responsive
to its market place and of becoming a platform for laboratory diagnostics. The
restructuring includes a reduction in the US based workforce of approximately 30
employees, a planned consolidation of the Company's US facilities into one and
restructuring charges of approximately $3.7 million. The Company anticipates a
reduction in the cash-burn rate to approximately $2 million per month by the end
of the third quarter and has set a target to reduce the cash-burn rate to $1
million per month by year end.
Neuromedical Systems, Inc. focuses intelligent vision on medicine.
Neuromedical's first product, the PapNet Testing System, increases the accuracy
of cervical screening by displaying potentially abnormal cells for review and
analysis by a cytology professional. The Company believes that increasing
access to routine screening and the adoption of PapNet testing can reduce the
morbidity and mortality associated with cervical cancer.
<PAGE>
Safe Harbor Statement
- ---------------------
Forward-looking statements discussed in this release are made under
the safe harbor provisions of the Private Securities Litigation Reform Act of
1995. Except for the historical information contained herein, the matters
discussed in this release are forward-looking statements which reflect the
Company's current views with respect to future events and financial performance,
which include, but are not limited to, statements regarding Company plans and
operations, management's assessments and decisions, marketing and promotion
strategy, and discussions of product development and performance. The words
"believe", "expect", "anticipate", "estimate", "project" and similar expressions
identify forward-looking statements, which speak only as of the date hereof.
Investors are cautioned that such forward looking statements involve risks and
uncertainties that could cause actual results to differ materially from
historical results or those anticipated due to many factors, including, but not
limited to, the Company's continuing negative cash flow, reliance on a single
product, competition, dependence on key personnel, the impact on the Company of
its territorial license agreements, dependence on patents and proprietary
technology, government regulation of products and advertising, limited marketing
and sales history, the impact of third-party reimbursement decisions, litigation
and other risks detailed in the Company's Securities and Exchange Commission
filings, including its 1997 Form 10-K and Exhibit 99.1 attached thereto. The
Company undertakes no obligation to publicly update or revise any forward-
looking statements.
###
<PAGE>
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized in Suffern, New York on this 8th day of
July, 1998.
NEUROMEDICAL SYSTEMS, INC.
By: /s/ Mark L. Smith
-------------------------------------------
Mark L. Smith
Vice President, Finance and
Administration and Chief Financial Officer
